Responses
Liver
PWE-128 Romiplostim’S Effect to Optimize SVR With Telapravir, Ribavirin, and Peg Interferon-Alfa 2A In Thrombocytopenic Cirrhotics with Chronic Hepatitis C. A Placebo Controlled Prospective Clinical Trial: Restraint C Trial
Compose a Response to This Article
Other responses
No responses have been published for this article.